Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses side effects associated with the novel HIF-2α inhibitor, MK-6482, for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma (RCC). Dr. Jonasch explains 86.9% of patients experienced primarily grade 1 or 2 anemia, which often improved without treatment; however, a few patients required exogenous EPO treatment. The second most common side effect was fatigue, which Dr. Jonasch suggests may not be a true side effect. Click here to learn more.